GlassScriptPhysician profile
Imge Hulur
NPI 1447600945
$5,059.74
in general payments reported to CMS, 2019-2025
20 companies · $971 in 2025
The $971 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $108 · 2021: $703 · 2022: $715 · 2023: $663 · 2024: $1,900 · 2025: $971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,416 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,415.92 |
| Education | $118.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,437.49 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $517.73 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $435.28 | 2022-2025 | Sotyktu |
| Incyte Corporation | $422.88 | 2022-2025 | Opzelura |
| Genzyme Corporation | $336.11 | 2021-2025 | |
| Janssen Biotech, INC. | $334.01 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $291.40 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $218.27 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $172.17 | 2020-2024 | Ilumya, Winlevi, Absorica Ld |
| Ucb, INC. | $166.88 | 2021-2023 | Bimzelx |
| Amgen INC. | $153.31 | 2020-2025 | Otezla, Otezla |
| Leo Pharma INC. | $131.25 | 2021-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $123.66 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $115.04 | 2021-2025 | Nemluvio |
| Pfizer INC. | $57.40 | 2022-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $39.34 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $34.38 | 2024-2025 | Zoryve |
| Biofrontera INC. | $30.33 | 2020-2021 | |
| Vyne Pharmaceuticals INC. | $26.40 | 2021 | |
| Nabriva Therapeutics, Plc | $16.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imge Hulur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.